Invented in 2012, CRISPR gene editing has proven curative in an exceptionally brief timeframe with the arrival of the first gene therapy to treat sickle cell disease in 2023. Read about how NIH has been in the midst of the CRISPR revolution and how researchers are expanding the technology to benefit more people.
A Showcase of Discoveries from NIH Intramural Labs and Clinics
On December 18, 2024, the scientific directors and clinical directors from each institute and center had three minutes and one slide to present a standout intramural research accomplishment from the past year. We highlight some of our favorites.
Global Collaboration Grows Expertise in Rwanda, Expands Research for Diabetes, Health Disparities, and More
Since 2016, the NIMHD–NIDDK–Rwandan Health Program has offered a yearlong opportunity for an early-career clinician scientist from Rwanda to train at the NIH, learn from our global community, and return to the country with first-hand experience in clinical research.
NIBIB-led Conference Leveraged Partnerships Across Engineering, Technology, and Biomedical Research
On October 22, 2024, the NIBIB hosted a daylong conference on the NIH campus, “Building Bridges Across NIH and the Broader Engineering Community,” to tap into the excitement surrounding the fantastic advances happening in the field of biomedical engineering.
Foundational Work at NIH and Today’s Transformative Treatments
For the 100,000 people in the United States and 8 million people worldwide with sickle cell disease (SCD), there are now two big reasons to be optimistic: Two FDA-approved gene therapies for SCD have been added to the armament of potentially curative therapies. We report on how NIH has been at the forefront of SCD research for decades and is advancing today's curative therapies.
Each year, the NIH Catalyst pays tribute in the January–February issue to NIH employees past and present who are no longer with us. Our condolences are with their friends, family, and colleagues who knew and loved them.
